Revvity Non-GAAP EPS of $1.18 beats by $0.04, revenue of $699M in-line

* Revvity press release [https://seekingalpha.com/pr/20279750-revvity-announces-financial-results-for-the-third-quarter-of-2025] (NYSE:RVTY [https://seekingalpha.com/symbol/RVTY]): Q3 Non-GAAP EPS of $1.18 beats by $0.04.
* Revenue of $699M (+2.8% Y/Y) in-line.
* Authorizes new $1 billion share repurchase program
* For the full year 2025, the Company is updating its full year revenue guidance to $2.83-$2.88 billion vs $2.85B consensus to reflect recent changes in foreign currency exchange rates and is reaffirming its organic growth guidance of 2% to 4%. The Company is also raising its adjusted EPS guidance to a range of $4.90 to $5.00 vs $4.86 consensus.

MORE ON REVVITY

* Revvity, Inc. (RVTY) Presents At Baird 2025 Global Healthcare Conference (Transcript) [https://seekingalpha.com/article/4821207-revvity-inc-rvty-presents-at-baird-global-healthcare-conference-2025-transcript]
* Revvity, Inc. (RVTY) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript [https://seekingalpha.com/article/4818897-revvity-inc-rvty-presents-at-wells-fargo-20th-annual-healthcare-conference-2025-transcript]
* Revvity: Not A Healthy Diagnosis For This Life Science Business [https://seekingalpha.com/article/4805386-revvity-not-healthy-diagnosis-life-science-business]
* Seeking Alpha's healthcare quant picks ahead of Q3 earnings: McKesson, Incyte top-rated stocks [https://seekingalpha.com/news/4503551-seeking-alphas-healthcare-quant-picks-ahead-of-q3-earnings-mckesson-incyte-top-rated-stocks]
* Short bets on S&P 500 Healthcare sector rises marginally to 1.91% in September; MRNA remains most shorted stock [https://seekingalpha.com/news/4503493-short-bets-on-sp-500-healthcare-sector-rises-marginally-to-191-in-september-mrna-remains-most-shorted-stock]